What's new, what's next?

PTSD Treatment for Veterans: What's Working, What's New, and What's Next.

More than a decade of war in the Middle East has pushed post-traumatic stress disorder (PTSD) to the forefront of public health concerns. The author defines the disorder and discusses risk factors, treatments, and the barriers to effective care.

Peace Ajiboye says your views matter.

HELLO EVERYONE and welcome to another edition of No Limits. My name is Peace Ajiboye and I am the new consultant editor of our magazine. For the next two years it will be my face that appears at the top of this column where we announce what's new and what's hot in nursing education. Take your time to read through this issue; there is sure to be something somewhere that's relevant to you.

Medicare: what's right? What's wrong? What's next?

Although future Medicare costs are highly uncertain, reasonable projections of those costs suggest a major financing problem. The Balanced Budget Act of 1997 will provide temporary relief, although it introduced some new problems, including its geographic adjustment of Medicare+Choice rates. For the future we propose a premium-support system and an expanded benefits package. Such a system would...

Syndrome X: what's old, what's new, what's etiologic?

Genetic epidemiology: Juvenile idiopathic arthritis genetics - What's new? What's next?

Studies have established the magnitude of the genetic basis of juvenile idiopathic arthritis (JIA). JIA is a complex genetic condition and the genes that influence susceptibility are actively being sought. A candidate gene approach is being used by several groups. MHC-, cytokine- and T-cell-related genes have all been positively associated with JIA. Here we review some of the latest genetic dat...

What's new and what's next.

Some of the latest developments in HIV treatment are described and contact information is given for people seeking further information on the topic. Clinical studies and preliminary results for interleukin-2 (IL-2), 1592U89 (abacavir), DMP-266 (efavirenz or Sustiva), and 141W94 (VX-94, Vertex) are described. Pharmaceutical companies are expected to continue developing new HIV drugs, including t...